A new paradigm for cancer treatment

Anti-angiogenic therapy alone can suppress the growth of established tumors but it can also potentiate the effects of radiation and chemotherapy through unknown mechanisms. In September Nature Medicine Rakesh Jain from Harvard Medical School suggests that anti-angiogenic therapy can also 'normalize' tumor vasculature before its destruction and this mechanism could be exploited to improve the anti-tumor effects of radio- and chemotherapy (Nat Med 2001, 7:987-989).Jain observed that the tumor vasc

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Anti-angiogenic therapy alone can suppress the growth of established tumors but it can also potentiate the effects of radiation and chemotherapy through unknown mechanisms. In September Nature Medicine Rakesh Jain from Harvard Medical School suggests that anti-angiogenic therapy can also 'normalize' tumor vasculature before its destruction and this mechanism could be exploited to improve the anti-tumor effects of radio- and chemotherapy (Nat Med 2001, 7:987-989).

Jain observed that the tumor vasculature is made up of a network of highly disorganized and abnormal blood vessels, which creates an obstacle for cancer treatments. But some anti-angiogenic therapies, such as blocking the vascular endothelial growth factor or its receptor (VEGFR2) induce epithelial cell apoptosis and produce a sort of circulation 'normalization' through elimination excess endothelial cells. This makes can make the immature tumor vessels more efficient before they destroy them.

Finding new imaging techniques and surrogate markers that permit quantification of specific vascular ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Tudor Toma

    This person does not yet have a bio.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo